Patient [Name/ID Number]

Name of epcoritamab treating physician

Treating physician's phone number (during office hours)

Treating physician's emergency care phone number (after office hours)

Next of kin emergency contact information

Date of first dose of epcoritamab

Version 1.0 July2024,
Approval date: 16Jul2024
MT-TEPK-240001

# Tepkinly™ (epcoritamab) Patient Card

**Please carry this card with you at all times. Show it to any healthcare provider who sees you and when you go to any hospital.**

Tell any healthcare provider who sees you that you are being treated with Tepkinly™ (epcoritamab).

If you get any side effects following your treatment with epcoritamab, please talk to your doctor or nurse.

Be careful while driving, cycling, or using heavy or potentially dangerous machines. If you have any of the symptoms described on this card, you should avoid these activities.

In addition, you can also report side effects directly using the Medicines Authority ADR reporting form, which is available online at http://www.medicinesauthority.gov.mt/adrportal,

and sent by post or email to;

Post: Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000

E-mail: postlicensing.medicinesauthority@gov.mt

Alternatively, they may be reported by contacting AbbVie's local representative V.J. Salomone Pharma Ltd. at +35699644126.

Version 1.0 July2024,
Approval date: 16Jul2024
MT-TEPK-240001

## Information for Patients

Epcoritamab may cause side effects which can be serious.

**Call your doctor or get emergency help immediately if you have any of the following symptoms:**

- Fever (38°C or higher)
- Dizziness or light-headedness
- Chills
- Fast heartbeat
- Difficulty/trouble breathing
- Headache
- Difficulty speaking or writing
- Drowsiness
- Confusion/disorientation
- Muscle weakness
- Seizures
- Memory loss

Version 1.0 July2024,
Approval date: 16Jul2024
MT-TEPK-240001

## Information for Healthcare Providers

- This patient is being treated with epcoritamab, a T-cell engaging bispecific antibody.
- Following treatment with epcoritamab, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) may occur, which may be serious if not treated promptly. CRS may occur several hours or days after epcoritamab administration, usually after the first full dose in Cycle 1. ICANS may occur several days or weeks after epcoritamab administration.

  For more information on Tepkinly, please refer to the Patient Information Leaflet which you can find from your treating physician or on the website https://www.tepkinly.eu/ where the patient card is also available.

- **Contact the patient's treating physician immediately for further information (contact details overleaf).**

Version 1.0 July2024,
Approval date: 16Jul2024
MT-TEPK-240001